The University of Chicago Header Logo

Connection

Jon Grant to Double-Blind Method

Back to Details
This is a "connection" page, showing publications Jon Grant has written about Double-Blind Method.
Jon Grant
Connection Strength
2.432
Double-Blind Method
  1. A randomised study and an extension study of brexpiprazole in patients with borderline personality disorder. Acta Neuropsychiatr. 2024 Nov 19; 37:e39.
    View in: PubMed
    Score: 0.165
  2. Silymarin (Milk Thistle) Treatment of Adults With Gambling Disorder: A Double-Blind, Placebo-Controlled Trial. Clin Neuropharmacol. 2024 Mar-Apr 01; 47(2):54-58.
    View in: PubMed
    Score: 0.157
  3. Double-Blind Placebo-Controlled Study of Memantine in Trichotillomania and Skin-Picking Disorder. Am J Psychiatry. 2023 05 01; 180(5):348-356.
    View in: PubMed
    Score: 0.146
  4. Tetrahydrocannabinol fails to reduce hair pulling or skin picking: results of a double-blind, placebo-controlled study of dronabinol. Int Clin Psychopharmacol. 2022 01 01; 37(1):14-20.
    View in: PubMed
    Score: 0.135
  5. Tolcapone in obsessive-compulsive disorder: a randomized double-blind placebo-controlled crossover trial. Int Clin Psychopharmacol. 2021 09 01; 36(5):225-229.
    View in: PubMed
    Score: 0.132
  6. A double-blind, placebo-controlled study of vortioxetine in the treatment of binge-eating disorder. Int J Eat Disord. 2019 07; 52(7):786-794.
    View in: PubMed
    Score: 0.111
  7. Milk Thistle Treatment for Children and Adults with Trichotillomania: A Double-Blind, Placebo-Controlled, Crossover Negative Study. J Clin Psychopharmacol. 2019 Mar/Apr; 39(2):129-134.
    View in: PubMed
    Score: 0.111
  8. Placebo response in trichotillomania. Int Clin Psychopharmacol. 2017 11; 32(6):350-355.
    View in: PubMed
    Score: 0.101
  9. Double-blind switch study of vilazodone in the treatment of major depressive disorder. Int Clin Psychopharmacol. 2017 05; 32(3):121-126.
    View in: PubMed
    Score: 0.098
  10. A double-blind, placebo-controlled study of inositol in trichotillomania. Int Clin Psychopharmacol. 2017 03; 32(2):107-114.
    View in: PubMed
    Score: 0.096
  11. N-Acetylcysteine in the Treatment of Excoriation Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2016 May 01; 73(5):490-6.
    View in: PubMed
    Score: 0.091
  12. The opiate antagonist, naltrexone, in the treatment of trichotillomania: results of a double-blind, placebo-controlled study. J Clin Psychopharmacol. 2014 Feb; 34(1):134-8.
    View in: PubMed
    Score: 0.078
  13. A randomized, placebo-controlled trial of N-acetylcysteine plus imaginal desensitization for nicotine-dependent pathological gamblers. J Clin Psychiatry. 2014 Jan; 75(1):39-45.
    View in: PubMed
    Score: 0.077
  14. Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry. 2010 Oct; 197(4):330-1.
    View in: PubMed
    Score: 0.062
  15. A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response. J Clin Psychopharmacol. 2010 Aug; 30(4):396-403.
    View in: PubMed
    Score: 0.061
  16. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence. Eur Neuropsychopharmacol. 2010 Nov; 20(11):823-8.
    View in: PubMed
    Score: 0.061
  17. N-acetylcysteine, a glutamate modulator, in the treatment of trichotillomania: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2009 Jul; 66(7):756-63.
    View in: PubMed
    Score: 0.057
  18. A double-blind, placebo-controlled study of the opiate antagonist, naltrexone, in the treatment of kleptomania. Biol Psychiatry. 2009 Apr 01; 65(7):600-6.
    View in: PubMed
    Score: 0.055
  19. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (Berl). 2008 Nov; 200(4):521-7.
    View in: PubMed
    Score: 0.053
  20. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry. 2008 May; 69(5):783-9.
    View in: PubMed
    Score: 0.052
  21. N-acetyl cysteine, a glutamate-modulating agent, in the treatment of pathological gambling: a pilot study. Biol Psychiatry. 2007 Sep 15; 62(6):652-7.
    View in: PubMed
    Score: 0.049
  22. Medication management of pathological gambling. Minn Med. 2006 Sep; 89(9):44-8.
    View in: PubMed
    Score: 0.047
  23. Escitalopram treatment of pathological gambling with co-occurring anxiety: an open-label pilot study with double-blind discontinuation. Int Clin Psychopharmacol. 2006 Jul; 21(4):203-9.
    View in: PubMed
    Score: 0.046
  24. Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006 Feb; 163(2):303-12.
    View in: PubMed
    Score: 0.045
  25. Sex differences in pain and hypothalamic-pituitary-adrenocortical responses to opioid blockade. Psychosom Med. 2004 Mar-Apr; 66(2):198-206.
    View in: PubMed
    Score: 0.039
  26. Role of adenosine A2A receptors in hot and cold cognition: Effects of single-dose istradefylline in healthy volunteers. Eur Neuropsychopharmacol. 2023 06; 71:55-64.
    View in: PubMed
    Score: 0.037
  27. Demographic and clinical features of 131 adult pathological gamblers. J Clin Psychiatry. 2001 Dec; 62(12):957-62.
    View in: PubMed
    Score: 0.034
  28. Personality dimensions in pathological gambling disorder and obsessive-compulsive disorder. Psychiatry Res. 2001 Nov 30; 104(3):205-12.
    View in: PubMed
    Score: 0.034
  29. Characteristics of geriatric patients seeking medication treatment for pathologic gambling disorder. J Geriatr Psychiatry Neurol. 2001; 14(3):125-9.
    View in: PubMed
    Score: 0.031
  30. Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study. Mov Disord. 2018 08; 33(8):1272-1280.
    View in: PubMed
    Score: 0.027
  31. Waiting Impulsivity: The Influence of Acute Methylphenidate and Feedback. Int J Neuropsychopharmacol. 2015 Jun 30; 19(1).
    View in: PubMed
    Score: 0.021
  32. Naltrexone improves quit rates, attenuates smoking urge, and reduces alcohol use in heavy drinking smokers attempting to quit smoking. Alcohol Clin Exp Res. 2014 Oct; 38(10):2622-9.
    View in: PubMed
    Score: 0.020
  33. Double-blind, placebo-controlled, pilot trial of paliperidone augmentation in serotonin reuptake inhibitor-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2013 Jun; 74(6):e527-32.
    View in: PubMed
    Score: 0.019
  34. N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry. 2013 Mar; 52(3):231-40.
    View in: PubMed
    Score: 0.018
  35. Effects of acute modafinil on cognition in trichotillomania. Psychopharmacology (Berl). 2010 Dec; 212(4):597-601.
    View in: PubMed
    Score: 0.015
  36. Atomoxetine modulates right inferior frontal activation during inhibitory control: a pharmacological functional magnetic resonance imaging study. Biol Psychiatry. 2009 Apr 01; 65(7):550-5.
    View in: PubMed
    Score: 0.014
  37. Naltrexone effect on physiological and subjective response to a cold pressor task. Biol Psychol. 2008 Feb; 77(2):233-6.
    View in: PubMed
    Score: 0.013
  38. A double-blind placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling. J Clin Psychiatry. 2002 Jun; 63(6):501-7.
    View in: PubMed
    Score: 0.009
  39. A preliminary report on possible naltrexone and nonsteroidal analgesic interactions. J Clin Psychopharmacol. 2001 Dec; 21(6):632-4.
    View in: PubMed
    Score: 0.008
  40. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001 Jun 01; 49(11):914-21.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.